Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib - Test2 - elhamkhani - TriplyDB

Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib

Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib

http://www.wikidata.org/entity/Q34332019

about

Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in mice Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity Modulatory effects of bortezomib on host immune cell functions Regulatory myeloid cells in transplantation Positive and negative regulation by NK cells in cancer Current and emerging strategies for the prevention of graft-versus-host disease Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells.Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity Current and future approaches for control of graft-versus-host disease.Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice.Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.Advances in graft-versus-host disease biology and therapy.Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.Proteasome: target for acute and chronic GVHD?Treatment of chronic graft-versus-host disease with bortezomib NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio Proteasome inhibitor bortezomib ameliorates intestinal injury in mice.Proteasome inhibitors in the treatment of multiple myeloma Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3.Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.Emerging therapies in hematopoietic stem cell transplantation Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.Infections in Hospitalised Patients with Multiple Myeloma: Main Characteristics and Risk Factors NFκB signaling drives pro-granulocytic astroglial responses to neuromyelitis optica patient IgG.Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation.A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.Autologous-allogeneic tandem stem cell transplantation in patients with multiple myeloma.Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation Inhibition of Proteasome Activity by Low-dose Bortezomib Attenuates Angiotensin II-induced Abdominal Aortic Aneurysm in Apo E(-/-) Mice.Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects

P2860

Q24288997-AB9F62DF-AB84-428B-9D5E-E90E68DEA755 Q24814325-D34CAC03-B792-4F42-87F4-21B5870B7B6F Q26751959-471119CB-1391-4C32-8A68-2B60679A89FE Q26771331-94EF8804-1EA8-4485-9B87-522985E086E3 Q26795618-8C13C379-CCB9-4D01-A6E6-350FB4E380C6 Q26999875-62A1B356-260B-488D-98A4-53A3DC123003 Q27004658-4D1E24FA-C67B-48E2-A501-5BAAF1BA27FF Q27016541-FE484CF2-D75A-47D1-AEA7-4953B3CB196D Q30486842-D08842A0-36AE-434A-AA70-7CE4858CB53E Q33262643-11542B70-CBF4-4DA2-A436-CF0438CF863E Q33316357-2B420388-89B0-427C-BD82-7E7F14BD9C46 Q33573863-18261EC6-B237-43A2-82A2-545B94487CB2 Q33642625-7D8B986E-991E-49E0-B164-9D56F3D614D3 Q33771667-845DB24E-7AA0-4FCC-9EEB-148D6812E0EB Q33792598-36A9D960-36AE-4B78-BE23-657A8E12D9BF Q33862527-E989B608-468C-418F-9B5B-4EFB0E260F5E Q34031916-CEA301B0-B5B8-4C0D-854C-9C24ECCB8849 Q34079116-ACB13679-9FBA-485B-963E-B4B2EBE13802 Q34136973-8C9C9CFA-AA3F-48EC-8D3D-893BFED40BBC Q34137032-7BB4F973-85B6-4952-930C-AFAD89E7EB2C Q34202277-C0FB3F83-BB74-40A0-B3F2-47FF0B63CFC0 Q34222685-8B60B417-B361-4364-8C1C-49C43434ED84 Q34611676-36225574-E60D-444E-B028-560FBC64FA16 Q34624143-4BD8FFB7-FB02-4E8C-82EC-8C1F818B51D1 Q34703720-CA6B8C6C-8E59-4B71-A8A0-3BF43E407B39 Q35586614-80D0E5CB-10A6-4411-94AB-9BD5660ABBE7 Q35737769-1F76FCD4-4689-4C20-AD78-FCC4B9883B62 Q35825522-8B2FA460-92E2-455B-AD86-740363DF1ADC Q35848453-2FD1460B-95F3-442B-9A6B-82C386EF453A Q36014986-45EBD82F-5B49-49C1-94B4-45FED626937B Q36038899-897CA0E5-902D-401F-A29B-90A616F25AF0 Q36110806-A8641824-DE35-418C-A12D-FD44C17375F8 Q36130498-D1601A1E-0B7B-4ED9-B6C3-5F55A710530A Q36157163-021275A5-9785-47EA-97EC-F1C750A6B585 Q36194663-ABDAB1E3-1678-4CDF-B9B7-05F4BD3E7972 Q36212400-08C8E9ED-7B16-42DC-A2D9-2D29915819B3 Q36217025-7AEAC23B-6C71-4F85-9B06-AA74AD228655 Q36251308-F33F9981-76B8-4561-95A3-251110A670DF Q36378038-9B244F3E-9FDC-4263-87B3-97AADF245CA3 Q36380188-3C2D509F-D4EC-4C4B-969F-F57D9F8E87DD

P2860

Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib

http://www.wikidata.org/entity/Q34332019

description

2004 nî lūn-bûn

@nan

2004 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Inhibition of acute graft-vers ...... roteasome inhibitor bortezomib

@ast

Inhibition of acute graft-vers ...... roteasome inhibitor bortezomib

@en

Inhibition of acute graft-vers ...... roteasome inhibitor bortezomib

@nl

type

label

Inhibition of acute graft-vers ...... roteasome inhibitor bortezomib

@ast

Inhibition of acute graft-vers ...... roteasome inhibitor bortezomib

@en

Inhibition of acute graft-vers ...... roteasome inhibitor bortezomib

@nl

prefLabel

Inhibition of acute graft-vers ...... roteasome inhibitor bortezomib

@ast

Inhibition of acute graft-vers ...... roteasome inhibitor bortezomib

@en

Inhibition of acute graft-vers ...... roteasome inhibitor bortezomib

@nl

P1433

Q34332019-4C465B3C-3598-4D6D-BDD0-713A9DE2ABFD

P1476

Q34332019-B8323428-A991-4A40-9EF2-CAB0D9F7AE13

P2093

Q34332019-4150113A-E6A2-48B5-80F8-3FA02426EE5D

Q34332019-623B97F2-9F52-4CF5-8260-E5EAA68F4BEC

Q34332019-8078D0AD-E933-490D-8358-B5CEE94D0C9E

Q34332019-840DC0F3-B36E-42F6-8C00-5DFFC0A26187

Q34332019-8E8B29B0-37FB-4E14-8B5B-B7BEABF941C8

Q34332019-98089E73-1014-4AFD-82D7-F0A52643F41E

Q34332019-9BB77615-81CF-44BE-A219-2572A7851819

Q34332019-C196C1E6-E0DC-4ABD-A34E-8467605301BA

Q34332019-F719C8CE-1243-4437-B3E5-367505D41565

P2860

Q34332019-0AF19E0E-E0DE-4D70-BC3D-B5BEDA018707

Q34332019-0CC33A5A-8950-4F73-BB65-879FD10483CE

Q34332019-11FF74B7-D17D-49A9-AA90-D3C77C649FFE

Q34332019-24186AC5-7E8B-4B85-93A6-4AD77D21C99A

Q34332019-4783AF0E-1F98-44E3-85D2-BB0DC6AACABB

Q34332019-4F4C2FE5-D5DB-405B-8405-52CD2379D7FA

Q34332019-4FBA1B82-E809-4535-A3EA-79CFE88F99DB

Q34332019-71448798-2F77-4425-9662-9D79FEEB9FE2

Q34332019-747B3F5F-BA9E-4C70-AD30-AA9887596BD4

Q34332019-85CD90F8-1573-49DA-A108-8CDE4ED44BC6

P304

Q34332019-60B25291-5370-4600-911D-471DFA16A7A7

P31

Q34332019-A794FC43-AF91-4A52-9A40-8B083811023A

P356

Q34332019-8BEBF228-712C-4C0C-958E-C081112969CA

P407

Q34332019-E7FDA066-77E2-4274-93B8-CC11950E70BD

P433

Q34332019-B2217F8B-35EE-487E-9A44-A09A5AAD71A4

P478

Q34332019-CFDC259C-8E0B-49FC-BD51-C02CD0E59BC7

P50

Q34332019-02188296-5E6C-4516-B0CD-B7E747CC3063

Q34332019-9ABE1043-FD34-455F-B204-5AD941B7B97E

Q34332019-A4EF1DF8-3D39-4BD8-B97D-5557609A6C13

Q34332019-A8BD7851-1CD3-4AE0-A8DB-1A77E50F4DC8

P577

Q34332019-8CF62494-4A3E-4E5A-90C6-2538D3DCF34D

P5875

Q34332019-1531DC10-6777-4E6C-B9CD-FE0F0D2A1AC1

P698

Q34332019-47F53B8C-AF7C-45BC-9EE2-A177F4695B90

P932

Q34332019-11F6D0DA-579F-4F72-AF78-E17A05172FE3

P356

PNAS.0401563101

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Inhibition of acute graft-vers ...... roteasome inhibitor bortezomib

@en

P2093

Christian Wysocki

http://www.w3.org/2001/XMLSchema#string

Haiyan Liu

http://www.w3.org/2001/XMLSchema#string

Isabel Barao

http://www.w3.org/2001/XMLSchema#string

Kai Sun

http://www.w3.org/2001/XMLSchema#string

Lisbeth A Welniak

http://www.w3.org/2001/XMLSchema#string

Matthew J O'Shaughnessy

http://www.w3.org/2001/XMLSchema#string

Thomas J Sayers

http://www.w3.org/2001/XMLSchema#string

William J Murphy

http://www.w3.org/2001/XMLSchema#string

William Riordan

http://www.w3.org/2001/XMLSchema#string

P2860

The NF-kappa B and I kappa B proteins: new discoveries and insights

NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses

Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

NF-kappa B: ten years after

Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

Microdialysis: intraoperative and posttraumatic applications in neurosurgery.

Ras regulation of NF-kappa B and apoptosis.

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

P304

8120-8125

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0401563101

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan S. Serody

Angela Panoskaltsis-Mortari

P577

2004-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8558559

http://www.w3.org/2001/XMLSchema#string

P698

15148407

http://www.w3.org/2001/XMLSchema#string

P932

419567

http://www.w3.org/2001/XMLSchema#string